D-1281-2020 Class III Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-1281-2020 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on May 26, 2020 and is designated Class III. Reason for recall: Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product. The recall status is terminated (terminated Nov 15, 2022). Affected quantity: 1,313,333 tablets.

Recall details

Product Type
Drugs
Report Date
Jun 3, 2020
Initiation Date
May 26, 2020
Termination Date
Nov 15, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,313,333 tablets

Product description

Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA, For repackaging by: AvKare Inc., Pulaski, TN 38478, Bulk Shipment, NDC 59746-247-97.

Reason for recall

Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

Distribution pattern

TN

Code information

Lot #s 19P0437 & 19P0438, Exp. 09/30/2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1281-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1281-2020. Report a data issue: hello@regdatalab.com.